28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
31 Jul
TORM-A
Mit syn på Torm, og hvorfor jeg mener der er penge at hente som investor.    Der er 95,7 mia. Torm-a..
25
31 Jul
ZEAL
Mange taler om LixiLan og hvor stort det kan blive - inklusiv mig selv!   Men Zealands lidt upræcise..
23
04 Aug
BAVA
hermed mit bidrag.   Kerrigsdale snakker om at man skal huske at bruge Apple to apple metoden (side ..
19
01 Aug
ZEAL
Jeg skrev igår et indlæg om et projekt hos Zealand Pharma som indenfor meget overskuelig fremtid kan..
16
31 Jul
 
Kan vi ikke få en service meddelelse på hvad der sker med alle de korrreanske spam indlæg der flyder..
15
29 Jul
OMXC20
Delfin har et indlæg om Varoufakis fra Lars Tvede som 10 personer har tomlet op. Læren er at Varoufa..
15
03 Aug
TORM-A
  Et kig på prospektet i Torm       13.4.2.2 Prospective consolidated financial information for the ..
11
01 Aug
EXQ
Jeg opdagede for et par uger siden at inrater.com havde lavet et system hvor man kunne oprette en mo..
11
29 Jul
I:DAX
Alpe påstår ikke som dig at kunne forudsige markedet i detaljer, derimod giver han bud på sandsynlig..
11
03 Aug
VWS
Energiwatch beskriver det ligefrem som at "Suzlon haler vinder ind på Vestas".   Hvad Børsen, Energi..
10

Novae Group plc : Interim results for the six months ended 30 June 2015

05/08/2015 07:00:23
                                                                                                                                                              ..

Stagecoach Group PLC : Director/PDMR Shareholding

04/08/2015 15:58:11
Stagecoach Group plc (the "Company") makes the following notification under the Financial Conduct Authority's Disclosure and Transparency Rule 3.1.4. On 4 Au..

Form 8.3 - Royal Dutch Shell plc

04/08/2015 13:50:55
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Coeur Reports Second Quarter 2015 Results
2
Medtronic, Inc. Commences Registered Exchange Offer for Certain of its Senior Notes
3
Marel hf. Issuance of Stock Options
4
Brad Keselowski Crew Chief Paul Wolfe Wins Second Straight MOOG® 'Problem Solver' Award After Wild Day at Pocono
5
LECTRA: Lectra's first apparel manufacturing seminar takes an in-depth look at the new rules of the changing fashion marketplace

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
05 August 2015 09:25:56
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150804.2 - EUROWEB4 - 2015-08-05 10:25:56 - 2015-08-05 09:25:56 - 1000 - Website: OKAY